Loading...
ARGX logo

argenx SENasdaqGS:ARGX Stock Report

Market Cap US$49.7b
Share Price
US$799.65
US$986.33
18.9% undervalued intrinsic discount
1Y37.6%
7D7.1%
Portfolio Value
​
View

argenx SE

NasdaqGS:ARGX Stock Report

Market Cap: US$49.7b

argenx (ARGX) Stock Overview

A commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. More details

ARGX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance2/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 65.3% below our estimate of its fair value

Earnings are forecast to grow 21.68% per year

Earnings grew by 55.1% over the past year

Risk Analysis

High level of non-cash earnings


ARGX Community Fair Values

Create Narrative

See what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives
UNCY logo
UNCYFeatured

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
View narrative
Community Contributor
US$21.53FV • 69.2% undervalued intrinsic discount
5419.8%Revenue growth p.a.
5.8k
17
0
112
2mo ago

argenx SE Competitors

Price History & Performance

Summary of share price highs, lows and changes for argenx
Historical stock prices
Current Share Price€799.65
52 Week High€934.62
52 Week Low€510.06
Beta-0.087
1 Month Change9.83%
3 Month Change1.42%
1 Year Change37.65%
3 Year Change108.79%
5 Year Change183.85%
Change since IPO3,376.74%

Recent News & Updates

Recent updates

argenx: TED Phase 3 Failure, Vyvgart Growth, And Why I'm Still A Hold

Dec 17

Argenx: The Magic May Be Already Priced In

Mar 24

argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent

Feb 27

argenx: Lofty Valuation Diminishes Appeal Amid Autoimmune Expansion (Rating Downgrade)

Jan 23

Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat

Oct 31

argenx: Myositis Data Could Add Billions In Value

Sep 25

Argenx: Strong Setup For Outperformance In 2025

Jun 28

argenx: Innovation Over Losses In Autoimmune Arena

May 07

argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion

Feb 01

Argenx files for US approval of subcutaneous form of neuromuscular disorder drug efgartigimod

Sep 21

Argenx's neuromuscular disorder drug Vyvgart wins approval in EU

Aug 11

Argenx SE GAAP EPS of -$3.81 beats by $0.83, total operating income of $85.18M

Jul 28

argenx: A Very Good Start For Vyvgart

May 25

argenx SE: Again Following Dutch Biotech, Prior Recommendation Near-Term Gain

May 18

argenx SE: Dutch Biotech Has Near Gain Ahead Says Hedging By Market-Makers

Mar 07

argenx: Vyvgart's Approval A Key Step For Continued Value Creation

Dec 22

argenx SE: Institutional Buying Turnaround In Dutch Biotech With Thin Audience Now Seen As Good Value By Market-Makers

Nov 30

argenx: R&D Day Goes Unnoticed

Aug 23

argenx: Next Phase Of Growth With Efgartigimod And ARGX-117

Jun 30

Shareholder Returns

ARGXUS BiotechsUS Market
7D7.1%-0.2%3.3%
1Y37.6%40.4%28.1%

Return vs Industry: ARGX underperformed the US Biotechs industry which returned 46.8% over the past year.

Return vs Market: ARGX exceeded the US Market which returned 29.7% over the past year.

Price Volatility

Is ARGX's price volatile compared to industry and market?
ARGX volatility
ARGX Average Weekly Movement4.3%
Biotechs Industry Average Movement10.9%
Market Average Movement7.1%
10% most volatile stocks in US Market16.1%
10% least volatile stocks in US Market3.3%

Stable Share Price: ARGX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: ARGX's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20081,863Tim Van Hauwermeirenargenx.com

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy.

argenx SE Fundamentals Summary

How do argenx's earnings and revenue compare to its market cap?
ARGX fundamental statistics
Market capUS$49.74b
Earnings (TTM)US$1.29b
Revenue (TTM)US$4.24b
38.5x
P/E Ratio
11.7x
P/S Ratio

Is ARGX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ARGX income statement (TTM)
RevenueUS$4.24b
Cost of RevenueUS$1.81b
Gross ProfitUS$2.42b
Other ExpensesUS$1.13b
EarningsUS$1.29b

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

May 07, 2026

Earnings per share (EPS)20.78
Gross Margin57.16%
Net Profit Margin30.50%
Debt/Equity Ratio0%

How did ARGX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/10 06:07
End of Day Share Price 2026/04/10 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

argenx SE is covered by 53 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Joel BeattyBaird
null nullBaird